Wendell Courtney, MD
Obstetrics & Gynecology · Leesburg, FLNPI 1639133572
Payments from drug & device makers
Across 49 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$212
- Vitrolife Inc.$163
- Daiichi Sankyo Inc.$142
- AbbVie$88
- Mylan Pharmaceuticals Inc.$87
- Shield Therapeutics Inc$84
- plus $518 from 17 others
What the payments were for
- Food & beverage$93272%
- Education$19915%
- Other$16313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $212 |
| Vitrolife Inc. | 1 | $163 |
| Daiichi Sankyo Inc. | 7 | $142 |
| AbbVie | 1 | $88 |
| Mylan Pharmaceuticals Inc. | 6 | $87 |
| Shield Therapeutics Inc | 5 | $84 |
| Pfizer | 4 | $76 |
| Mayne Pharma Commercial LLC | 2 | $69 |
| Organon | 3 | $50 |
| Cepheid | 1 | $47 |
| Roche Diagnostics Corporation | 2 | $45 |
| Exeltis, USA Inc. | 2 | $42 |
| Avion Pharmaceuticals | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $18 |
| Innovation Technologies Inc | 1 | $17 |
| Myovant Sciences Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Merck | 1 | $15 |
| KCI USA, Inc. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $12 |
| Molnlycke Health Care US, LLC | 1 | $11 |
How this compares
$1,294 in reported general payments places this provider in the 55th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 113 | $3,144 |
| Oxybutynin Chloride ErOxybutynin Chloride | 20 | $541 |
| Medroxyprogesterone Acetate | 29 | $523 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $266 |
| ProgesteroneProgesterone, Micronized | 15 | $245 |
| Metronidazole | 12 | $64 |
| Norethindrone-E.Estradiol-Iron | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Leesburg
- Douglas MoffettLeesburg$1.7M
- Samuel LedermanLake Worth$13.4M
- Richard MyersJacksonville$2.7M
- Guillermo LievanoMiami$2.5M
- Steven McCarusCelebration$2.3M
- Samuel WolfPanama City$2.1M
- Rafael Garcia-OcasioHialeah$2M
- Harvey GlasserAventura$1.6M
- Jorge PandoMiami Lakes$1.5M
- Victoria BedellMiami$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.